Get the Stockscreener App
76.50
39.65%
21.72
After Hours:
76.72
0.22
+0.29%
Forte Biosciences Inc stock is traded at $76.50, with a volume of 17.54M.
It is up +39.65% in the last 24 hours and up +263.77% over the past month.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
See More
Previous Close:
$54.78
Open:
$76.41
24h Volume:
17.54M
Relative Volume:
23.62
Market Cap:
$1.57B
Revenue:
-
Net Income/Loss:
$-75.86M
P/E Ratio:
-14.98
EPS:
-5.1069
Net Cash Flow:
$-59.39M
1W Performance:
+61.09%
1M Performance:
+263.77%
6M Performance:
+115.31%
1Y Performance:
+559.48%
1-Day Range:
$76.38
$76.60
1-Week Range:
$48.56
$76.60
52-Week Range:
$9.10
$76.60
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
76.50 | 1.12B | 0 | -75.86M | -59.39M | -5.1069 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
argenx (FBRX counterparty) plans full-share tender offer for Forte Biosciences - Stock Titan
Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders - MedCity News
The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today - Barchart.com
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx - Wilson Sonsini
Argenx to acquire Forte Biosciences for $2.2 billion - Drug Discovery News
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Forte Biosciences, Inc. (NASDAQ: FBRX) - Morningstar
Shareholder Alert: Ademi LLP investigates whether Forte Biosciences, Inc. is obtaining a Fair Price for Public Shareholders - Morningstar
Forte: 'Hold' On Positive FB102 Vitiligo Treatment Data And argenx Acquisition For $2.2 Billion - Seeking Alpha
Argenx to Acquire Forte Biosciences for $2.2B, Bolstering Autoimmune Pipeline - Briefs Finance
FBRX Stock Extends Surge As Barclays Lifts Target On FB102 Momentum - StocksToTrade
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B - Proactive financial news
Argenx expands immune pipeline in $2.2B cash acquisition of Forte - BioWorld News
argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX) - Seeking Alpha
argenx Expands Immunology Pipeline with Forte Biosciences Acquis - GuruFocus
Forte Biosciences Inc (FBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
argenx to Acquire Forte Biosciences for $2.2 Billion, Adding Anti-CD122 Antibody FB102 - BioPharm International
Forte Biosciences Surges on $2.2 Billion Cash Buyout Deal - Quiver Quantitative
argenx boosts immuno expertise with buy of Forte Biosciences - The Pharma Letter
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
Argenx to acquire Forte Biosciences for $2.2B - Axios
argenx to Acquire Forte Biosciences for $77.00 Per Share in Cash Deal - Kalkine Media
argenx to Acquire Forte Biosciences for $2.2 Billion - Contract Pharma
FBRX Stock Extends Rally As Barclays Lifts Biotech Hopes - StocksToTrade
Argenx (ARGX.US) makes a bold $2.2 billion acquisition of Forte Biosciences (FBRX.US) at a 40% premium, strengthening its immunology drug portfolio. - Bitget
argenx Acquires Forte Biosciences for $2.2 Billion - Pharmaceutical Executive
FBRX Stock Surges As Barclays Backs FB102 Breakthrough - timothysykes.com
argenx to buy Forte Bio for $2.2B in immunology push - FirstWord Pharma
Freshfields-Led Drug Co. To Buy Forte Biosciences For $2.2B - Law360
TD Cowen downgrades Forte Biosciences stock rating on Argenx deal By Investing.com - Investing.com Canada
TD Cowen downgrades Forte Biosciences stock rating on Argenx deal - Investing.com
argenx to Acquire Forte Biosciences in $2.2 Billion Deal to Expand Autoimmune Pipeline - citybiz
argenx SE (ARGX) to Acquire Forte Biosciences (FBRX) for $2.2B - GuruFocus
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy - BioSpace
argenx To Acquire Forte Biosciences For $2.2 Billion, Adding Anti-CD122 Antibody FB102 To Immunology Pipeline - Pulse 2.0
Forte Biosciences stock surges 39% on argenx acquisition deal By Investing.com - Investing.com India
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Stocks making the biggest moves premarket: Micron Technology, Forte Biosciences, ExxonMobil, Baker Hughes & more - CNBC
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug - Yahoo Finance
Forte Biosciences stock surges 39% on argenx acquisition deal - Investing.com
FBRX Stock On Track For Highest Levels In Over 4.5 Years As ArgenX Scoops Up Autoimmune Drug Maker - Stocktwits
Forte Biosciences Agrees to Be Acquired by Argenx in $2.2 Billion Deal - marketscreener.com
Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx - Yahoo Finance
Argenx agrees $2.2 billion acquisition of Forte Biosciences to strengthen autoimmune drug pipeline - Yahoo Finance
Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B - Endpoints News
Forte Biosciences to be acquired by argenx - TipRanks
Argenx pens $2.2bn deal to buy autoimmune biotech Forte - pharmaphorum
Argenx (ARGX) to Acquire Forte Biosciences for $2.2 Billion - GuruFocus
Forte Biosciences to Be Acquired by argenx in $77-Per-Share Tender Offer and Merger - TradingView
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug - Fierce Biotech
argenx to acquire Forte Biosciences (Nasdaq: FBRX) in $2.2B all-cash deal - Stock Titan
Forte surges in premarket as Argenx agrees $2.2 billion acquisition By Investing.com - Investing.com Canada
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):